Resultados: 69

Risk of acute kidney injury and cost-effectiveness analysis comparing vancomycin and linezolid for the treatment of pediatric patients infected with Gram-positive bacteria

Oliveira, Laiane de Jesus; Ricieri, Marinei Campos; Fachi, Mariana Milan; Okumura, Lucas Miyake; Motta, Fábio Araújo.

J. bras. econ. saúde (Impr.); 14 (Suplemento 2), 2022

Objective: This study aimed to compare the occurrence of acute kidney injury (AKI) in pediatric patients who used vancomycin (VAN) or linezolid (LNZ) to treat Gram-positive coccus (GPC) infections and to assess which treatment (VAN or LNZ) is the most cost-effective considering a pediatric hospital persp...

Insuficiência Renal, Vancomicina, Linezolida, 50303, Pediatria

Texto completo

Statements about hemophilia A in Brazil: an expert Delphi panel

Magliano, Carlos Alberto da Silva; Pereira, Ana a Carolina Padula Ribeiro; Fernandes, Roberta Arinelli; Sato-Kuwabara, Yukie; Loze, Priscilla Magalhães; Carlos, Nayara da Silva; Mata, Verónica Elizabeth.

J. bras. econ. saúde (Impr.); 14 (1), 2022

Objective: Understanding unmet needs related to hemophilia A management in Brazil is critical for supporting decision-making. Methods: A modified Delphi consensus panel was conducted. Hematologists with extensive experience treating hemophilia in the Brazilian Public Health System were invited to answer ...

Hemofilia B, Prevenção de Doenças, Terapêutica

Texto completo

Healthcare resource utilization of spinal muscular atrophy in the Brazilian Unified Health System: a retrospective database study

Barbour, Julio; Araújo, Alexandra Prufer de Queiroz Campos; Zanoteli, Edmar; França Junior, Marcondes Cavalcante; Ritter, Alessandra Mileni Versuti; Casarin, Fabiana; Julian, Guilherme Silva; Yazawa, Priscila; Mata, Veronica Elisabeth; Carlos, Nayara da Silva.

J. bras. econ. saúde (Impr.); 13 (2), 2021

Objective: To describe the healthcare resource utilization (HCRU) related to patients with spinal muscular atrophy (SMA) treated at the Brazilian Unified Health System (SUS) since 2015 according to age-groups. Methods: This study analyzed outpatient and inpatient data for SMA patients from the Brazilian ...

Atrofia Muscular Espinal, Sistema Único de Saúde, Doenças Raras

Texto completo (link principal)     Texto completo (link alternativo)    

The use of micro-costing in an economic analysis of allogeneic HSCT in Brazil

Vargas, Dora Fraga; de David, Caroline Nespolo; Horvath, Jaqueline Driemeyer Correia; Silva, Tatiana Schnorr; Pereira, Mariana Pinto; Rigoni, Lisandra Della Costa; Sartor, Ivaine Tais Sauthier; Zavaglia, Gabriela Oliveira; Kern, Luciane Beatriz; Luft, Thainá Dias; Tolves, Fernanda Lutz; Scherer, Fernanda Fetter; Pereira, Jaina da Costa; Barrionuevo, Fabiano; Etges, Ana Paula Beck da Silva; Zanotto, Bruna Stella; Daudt, Liane Esteves; Cruz, Luciane Nascimento; Polanczyk, Carisi Anne; Astigarraga, Claudia Caceres.

J. bras. econ. saúde (Impr.); 13 (2), 2021

Objetivo: O objetivo deste estudo foi estimar os custos do tratamento do transplante de células--tronco hematopoéticas (TCTH) em um centro de referência no Brasil. Métodos: A população do estudo foi composta por pacientes provenientes da lista de TCTH do Sistema Único de Saúde submetidos ao TCTH ...

Custos e Análise de Custo, Transplante de Células-Tronco Hematopoéticas

Texto completo (link principal)     Texto completo (link alternativo)    

Enough with the madness: a systematic review and meta-analysis of hydroxychloroquine for COVID-19

Santos, André Soares; Gonçalves, Érica Sandy Dias; Oliveira, Ananda Jessyla Felix; Lima, Douglas Borges; Noronha, Kenya Valéria Micaela de Souza; Andrade, Mônica Viegas.

J. bras. econ. saúde (Impr.); 13 (2), 2021

Objective: Because of preliminary results from in vitro studies, ydroxychloroquine (HCQ) and chloroquine (CQ) have been proposed as possible treatments for COVID-19, but the clinical evidence is discordant. This study aims to evaluate the safety and efficacy of CQ and HCQ for the treatment of COVID-19. M...

COVID-19, Cloroquina, Hidroxicloroquina, Revisão Sistemática

Texto completo (link principal)     Texto completo (link alternativo)    

Application of the MCDA method for assessing new technologies for familial hypercholesterolaemia treatment

Santos, Marisa da Silva; Morais, Quenia Cristina Dias; Cramer, Helena; Assad, Marcelo; Tura, Bernardo; Santos-Jr, Braulio; Nascimento, Aline do.

J. bras. econ. saúde (Impr.); 13 (1), 2021

Objective: Familial hypercholesterolaemia is a hereditary disease characterized by very high levels of low-density lipoprotein cholesterol and an elevated risk of early-onset cardiovascular disorders. New drugs provide alternatives for the treatment of patients with homozygous familial hypercholesterolae...

Hiperlipoproteinemia Tipo II, Avaliação da Tecnologia Biomédica, Tomada de Decisões

Texto completo (link principal)     Texto completo (link alternativo)    

Comparative analysis between prevention and treatment costs for gestational diabetes mellitus in primary and tertiary health care in a city in Southern Brazil

Reichenbach, Ricardo; Reis, Yasmin Cristina Ricardo dos; Gullo, Maria Carolina Rosa; Madi, Jose Mauro; Rahmi, Rosa Maria.

J. bras. econ. saúde (Impr.); 13 (1), 2021

Objective: The present study’s purpose is to evaluate the economic context in which the Brazilian public health system, the only universal public health system with more than 200 million users, stands out. This evaluation will be made through the lens of the execution of gestational health care service...

Diabetes Gestacional, Alocação de Custos, Atenção Primária à Saúde, Atenção Secundária à Saúde

Texto completo (link principal)     Texto completo (link alternativo)    

Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system

Oliveira, Ana Paula Casagrande Drozda; Roubik, Camila Finardi; Dyer, Matthew T. D; Neusquen, Lucienne Pereira Del Grossi; Marcolino, Miriam Allein Zago; Ribeiro, Rodrigo Antonini; May, Jessica R.

J. bras. econ. saúde (Impr.); 13 (3), 2021

Objective: To perform an analysis over time of the number needed to treat (NNT) and the cost of preventing an event (COPE) for nivolumab + ipilimumab (NIVO+IPI) and pembrolizumab + axitinib (PEMBRO+AXI) as first-line treatments for advanced renal cell carcinoma patients with intermediate or poor-risk, un...

Carcinoma de Células Renais, Axitinibe, Custos e Análise de Custo, Custos de Cuidados de Saúde, Nivolumabe

Texto completo (link principal)     Texto completo (link alternativo)    

Rotational thromboelastometry in the perioperative period of cardiac surgeries: cost-effectiveness analysis and budget impact

Santos, André Soares; Oliveira, Ananda Jessyla Felix; Fernandes, Magda Lourenço; Nogueira, José Luiz dos Santos; Noronha, Kenya Valéria Micaela de Souza; Andrade, Mônica Viegas.

J. bras. econ. saúde (Impr.); 12 (3), 2020

Objective: The transfusion of blood components and blood products in cardiac surgery patients can be guided by protocols based on standard laboratory tests and/or clinical decisions (Standardof-Care, SOC) or viscoelastic haemostatic assays (VHA). The aim of this study is to evaluate the cost-effectivenes...

Tromboelastografia, Coagulação Sanguínea, Cirurgia Torácica, Avaliação da Tecnologia Biomédica, 50303

Texto completo (link principal)     Texto completo (link alternativo)    

Cost-effectiveness analysis and budgetary impact of antipsychotics available in the Brazilian Unified Health System

Vianna, Cid Manso de Mello; Fernandes, Ricardo Ribeiro Alves; Mosegui, Gabriela Bittencourt Gonzalez; Pagnin, Valéria Queiroz.

J. bras. econ. saúde (Impr.); 12 (3), 2020

Objective: To carry out a cost-effectiveness and budget impact analysis of antipsychotic use in adults to treat schizophrenia from the perspective of the Unified Health System (SUS). Methods: A Markov model simulated the treatment of schizophrenic patients with an initial average age of 25 years and a li...

Análise Custo-Benefício, Análise de Impacto Orçamentário de Avanços Terapêuticos, Esquizofrenia, Antipsicóticos, Avaliação da Tecnologia Biomédica

Texto completo (link principal)     Texto completo (link alternativo)